



5 December 2022

ASX Code: MXC

LSE Code: MXC

Delivery of US\$1 million order of ArtemiC™ to AMC Holdings completed

Key Highlights:

- US\$1,000,000 delivery of ArtemiC™ to US distribution partner AMC Holdings completed.
- The ArtemiC™ delivery is MGC Pharma's largest delivery into the US market to date.

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, is pleased to announce that it has completed the delivery of its largest order of **ArtemiC™** to US distribution and marketing partner, AMC Holdings Inc. (AMC).

Delivery to AMC Holdings

As announced in MGC Pharma's market release titled "Operations Update" on 20 October 2022, AMC Holdings, amended the terms of its US\$1,000,000 order of **ArtemiC™** Rescue, with the product to be delivered in a single shipment, and to be ready for immediate supply in the US owing to increasing demand.

Delivery of this large consignment of **ArtemiC™** has now been completed, marking the first substantial commercial delivery of the product under the AMC US supply and distribution agreement to date.

Brent W. Yessin of AMC commented, "AMC are excited to bring the first commercial order of **ArtemiC™** into the US. It will be available both on-line and through independent pharmacies. Since the pandemic, the federal government has stopped paying for many treatments the cost burden has shifted to the individual states and consumers. With this change in policy AMC are pleased to be in a position offer the market a natural, plant based and clinically tested treatment option¹".

--Ends--

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.eu

UK Financial and Corporate Advisor

Hannam & Partners
Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

MGC Pharmaceuticals Ltd

David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.eu

UK Broker

Turner Pope
Andy Thacker
+44 203 657 0050
info@turnerpope.com

¹ <https://www.asx.com.au/asxpdf/20201215/pdf/44qyzvd1ggtz3z.pdf>

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    